2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: Thomas Hach

Poster-Quality of Life and Outcomes

October 25, 2021

Patient-Reported Outcome Measures in Multiple Sclerosis Clinical Trials: Critical Assessment and Insights from People Living with Multiple Sclerosis

Background: Multiple sclerosis (MS) clinical trials often include patient-reported outcomes (PROs) to quantify treatment effects not...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study

Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Dual Mode of Action of Siponimod in Secondary Progressive Multiple Sclerosis: A Hypothesis Based on the Relevance of Pharmacological Properties

Background: Siponimod, a potent and selective sphingosine 1-phosphate (S1P1,5) receptor modulator, is the first oral disease-modifying...

Read More →

Platform-Disease Management

October 25, 2021

Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire

Background: The validated physician-completed MSProDiscussTM tool facilitates physician-patient interaction in evaluating early signs of...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC